Literature DB >> 34286440

CXCL11 Signaling in the Tumor Microenvironment.

Qun Gao1, Yi Zhang2.   

Abstract

CXCL11 which can bind to two different chemokine receptors, CXCR3 and CXCR7, has found a prominent place in current tumor research. In this chapter, we mainly discuss the current evidence on the role of the immune response of CXCL11 in tumor microenvironment (TME). The diverse functions of CXCL11 include inhibiting angiogenesis, affecting the proliferation of different cell types, playing a role in fibroblast directed carcinoma invasion, increasing adhesion properties, suppressing M2 macrophage polarization, and facilitating the migration of certain immune cells. In addition, we discussed the application of CXCL11 as an adjuvant to various mainstream anti-cancer therapies and the future challenges in the application of CXCL11 targeted therapies.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Angiogenesis; CXCL11; CXCR3; CXCR7; Cell adhesion; Cytotoxic T lymphocytes; Fibroblast migration; Immune cells; Immune cells migration; Polarization of immune cells; Proliferation; Self-renewal; Tumor microenvironment; Tumorigenicity; vvDD-CXCL11

Mesh：

Substances：

Year:  2021        PMID： 34286440     DOI： 10.1007/978-3-030-62658-7_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  36 in total

Review 1.  CXC chemokines in angiogenesis.

Authors:  J A Belperio; M P Keane; D A Arenberg; C L Addison; J E Ehlert; M D Burdick; R M Strieter
Journal:  J Leukoc Biol       Date:  2000-07       Impact factor: 4.962

2.  A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells.

Authors:  Amit Awasthi; Yijun Carrier; Jean P S Peron; Estelle Bettelli; Masahito Kamanaka; Richard A Flavell; Vijay K Kuchroo; Mohamed Oukka; Howard L Weiner
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

3.  Development of a novel chemokine-mediated in vivo T cell recruitment assay.

Authors:  Gabriele S V Campanella; Benjamin D Medoff; Lindsay A Manice; Richard A Colvin; Andrew D Luster
Journal:  J Immunol Methods       Date:  2008-01-09       Impact factor: 2.303

4.  The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27.

Authors:  Lionel Apetoh; Francisco J Quintana; Caroline Pot; Nicole Joller; Sheng Xiao; Deepak Kumar; Evan J Burns; David H Sherr; Howard L Weiner; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2010-08-01       Impact factor: 25.606

5.  Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors.

Authors:  Zinal S Chheda; Rajesh K Sharma; Venkatakrishna R Jala; Andrew D Luster; Bodduluri Haribabu
Journal:  J Immunol       Date:  2016-07-27       Impact factor: 5.422

6.  In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression.

Authors:  Yiwei Chu; Xiuli Yang; Wei Xu; Ying Wang; Qiang Guo; Sidong Xiong
Journal:  Cancer Immunol Immunother       Date:  2007-02-14       Impact factor: 6.968

7.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Authors:  Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

8.  STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.

Authors:  Katrina K Au; Cécile Le Page; Runhan Ren; Liliane Meunier; Isabelle Clément; Kathrin Tyrishkin; Nichole Peterson; Jennifer Kendall-Dupont; Timothy Childs; Julie-Ann Francis; Charles H Graham; Andrew W Craig; Jeremy A Squire; Anne-Marie Mes-Masson; Madhuri Koti
Journal:  J Pathol Clin Res       Date:  2016-09-19

9.  Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.

Authors:  B Cambien; B F Karimdjee; P Richard-Fiardo; H Bziouech; R Barthel; M A Millet; V Martini; D Birnbaum; J Y Scoazec; J Abello; T Al Saati; M G Johnson; T J Sullivan; J C Medina; T L Collins; A Schmid-Alliana; H Schmid-Antomarchi
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

10.  Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.

Authors:  K E Cole; C A Strick; T J Paradis; K T Ogborne; M Loetscher; R P Gladue; W Lin; J G Boyd; B Moser; D E Wood; B G Sahagan; K Neote
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307
View more
  4 in total

1.  Oxaliplatin inhibits colorectal cancer progression by inhibiting CXCL11 secreted by cancer-associated fibroblasts and the CXCR3/PI3K/AKT pathway.

Authors:  Caifu Lu; Cong Zhang
Journal:  Clin Transl Oncol       Date:  2022-09-21       Impact factor: 3.340

Review 2.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

3.  Tumor Immune Microenvironment Related Gene-Based Model to Predict Prognosis and Response to Compounds in Ovarian Cancer.

Authors:  Jiang Yang; Shasha Hong; Xiaoyi Zhang; Jingchun Liu; Ying Wang; Zhi Wang; Likun Gao; Li Hong
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 4.  Emerging role of different DNA methyltransferases in the pathogenesis of cancer.

Authors:  Pengcheng Liu; Fan Yang; Lizhi Zhang; Ying Hu; Bangjie Chen; Jianpeng Wang; Lei Su; Mingyue Wu; Wenjian Chen
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.